Mastic gum has no effect on Helicobacter pylori load in vivo

Bebb, James R.

doi:10.1093/jac/dkg366

Cited by 42 publications

(30 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mastic has also been reported to possess antioxidant [12] and antibacterial [13] activity. With reference to gastrointestinal disorders, the effectiveness of the resin against peptic ulcers is evident [14] in most studies, while only in two reports there is no effect on H pylori eradication in vivo [15,16] . Furthermore, regarding gastric mucosa, the plant has been shown to be hepatoprotective in tetrachloride-intoxicated rats [17] and to suppress the extent of iron-induced lipid peroxidation in rat liver homogenates [18] , without any toxic effect.…”

Section: Introductionmentioning

confidence: 99%

Chios mastic treatment of patients with active Crohn’s disease

Kaliora

Stathopoulou²,

Triantafillidis³

et al. 2007

WJG

View full text Add to dashboard Cite

AIM:To evaluate the effectiveness of mastic administration on the clinical course and plasma inflammatory mediators of patients with active Crohn's disease (CD). METHODS:This pilot study was conducted in patients with established mild to moderately active CD, attending the outpatient clinics of the hospital, and in healthy controls. Ten patients and 8 controls were recruited for a 4-wk treatment with mastic caps (6 caps/d, 0.37 g/cap). All patients successfully completed the protocol. CD Activity Index (CDAI), Nutritional Risk Index (NRI), C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), monocyte chemotactic protein-1 (MCP-1), and total antioxidant potential (TAP) were evaluated in the plasma at baseline and at the end of the treatment period. Results were expressed as mean values ± SE and P < 0.05 was considered to indicate statistical significance. RESULTS:Patients exhibited significant reduction of CDAI (222.9 ± 18.7 vs 136.3 ± 12.3, P = 0.05) as compared to pretreament values. Plasma IL-6 was significantly decreased (21.2 ± 9.3 pg/mL vs 7.2 ± 2.8 pg/ mL, P = 0.027), and so did CRP (40.3 ± 13.1 mg/mL vs 19.7 ± 5.5, P = 0.028). TAP was significantly increased (0.15 ± 0.09 vs 0.57 ± 0.15 mmol/L uric acid, P = 0.036). No patient or control exhibited any kind of side effects. CONCLUSION:The results suggest that mastic significantly decreased the activity index and the plasma levels of IL-6 and CRP in patients with mildly to moderately active CD. Further double-blind, placebo-controlled studies in a larger number of patients are required to clarify the role of this natural product in the treatment of patients with CD.

show abstract

Section: Introductionmentioning

confidence: 99%

Chios mastic treatment of patients with active Crohn’s disease

Kaliora

Stathopoulou²,

Triantafillidis³

et al. 2007

WJG

View full text Add to dashboard Cite

show abstract

“…However, in a more recent in vivo study of H. pylori infection, the activity of mastic gum was compared with antibiotic eradication schemes, and after a 7-day therapy no eradication of the bacterium from the stomachs of mice receiving mastic was observed (17). Finally, H. pylori-positive patients were treated with mastic capsules for 7 days, and they all remained H. pylori positive after the administration (6). The last two studies concluded that no "antibiotic-like" activity should be expected from crude mastic.…”

mentioning

confidence: 99%

In Vitro and In Vivo Activities of Chios Mastic Gum Extracts and Constituents against Helicobacter pylori

Paraschos

Magiatis

Mitakou

et al. 2007

Antimicrob Agents Chemother

142

111

View full text Add to dashboard Cite

The extracts and pure major constituents of Chios mastic gum (resin of Pistacia lentiscus var. chia) were tested for their activities against Helicobacter pylori. A total mastic extract without polymer (TMEWP) was prepared after removal of the contained insoluble polymer in order to ameliorate solubility and enhance in vivo activity. Administration of TMEWP to H. pylori SS1-infected mice over the period of 3 months with an average dose of 0.75 mg/day led to an approximately 30-fold reduction in the H. pylori colonization (1.5 log CFU/g of tissue). However, no attenuation in the H. pylori-associated chronic inflammatory infiltration and the activity of chronic gastritis was observed. To further characterize potential active mastic constituents, the TMEWP was separated into an acidic and a neutral fraction. Both were extensively characterized by nuclear magnetic resonance and mass spectroscopy to elucidate the structure of the components contained within each fraction. After chromatographic separation, the acid fraction gave the major triterpenic acids, while the neutral fraction gave several triterpenic alcohols and aldehydes. Mastic extracts and isolated pure triterpenic acids were tested for in vitro activity against a panel of 11 H. pylori clinical strains. The acid fraction was found to be the most active extract (minimum bactericidal concentration [MBC], 0.139 mg/ml), and the most active pure compound was isomasticadienolic acid (MBC, 0.202 mg/ml [0.443 mM]). Our results show that administration of TMEWP may be effective in reducing H. pylori colonization and that the major triterpenic acids in the acid extract may be responsible for such an activity.

show abstract

“…Most Chios mastic doses previously reported in human studies were around this level, e.g. 5 g/day/person (Triantafyllou et al, 2007), 4 g/day/person (Bebb et al,2003), 2.2 g/day/parson (Kaliora et al, 2007a(Kaliora et al, , 2007b, or 1 g/day/person (Al-Habbal et al, 1984). Favorable effects of mastic such as anticarcinogenic potential could be achieved at relatively low doses without any toxicity (He et al, 2006).…”

Section: Chios Mastic (Pistacia Lentiscus L) and Cancer Chemopreventionmentioning

confidence: 96%